| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Paul I Terasaki | |
| P2860 | cites work | Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes | Q77859935 |
| Kidney graft failure and presensitization against HLA class I and class II antigens | Q78021242 | ||
| Slow release salbutamol and Tedral in the treatment of reversible airways obstruction | Q95780992 | ||
| Anti-HLA antibodies after solid organ transplantation | Q33856062 | ||
| Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies | Q34205519 | ||
| Acute humoral renal allograft rejection | Q34540973 | ||
| Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment | Q34977911 | ||
| Immunologic monitoring in lung allograft recipients | Q38362456 | ||
| A large, single center investigation of the immunogenetic factors affecting liver transplantation | Q38496955 | ||
| Association between treatment-resistant kidney-allograft rejection and post-transplant appearance of antibodies to donor B-lymphocyte alloantigens | Q39476608 | ||
| MICA is a target for complement-dependent cytotoxicity with mouse monoclonal antibodies and human alloantibodies | Q40742227 | ||
| Flow cytometry crossmatching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants. | Q40769068 | ||
| Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts | Q40793332 | ||
| MICA, a new polymorphic HLA-related antigen, is expressed mainly by keratinocytes, endothelial cells, and monocytes. | Q41069294 | ||
| Biochemical and immunological evaluation of donor-specific soluble HLA in the circulation of liver transplant recipients | Q41182796 | ||
| Pre-transplant anti-epithelial cell antibodies and graft failure after single lung transplantation | Q41366720 | ||
| Sensitization and sensitivity: defining the unsensitized patient | Q42625884 | ||
| Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome | Q43460126 | ||
| Posttransplant immune monitoring of anti-HLA antibody | Q43552594 | ||
| Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques | Q43618124 | ||
| Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection | Q43685024 | ||
| Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection | Q43747982 | ||
| Mycophenolate mofetil decreases antibody production after cardiac transplantation | Q43880383 | ||
| Immunoadsorption of sensitized kidney transplant candidates immediately prior to surgery | Q43967327 | ||
| Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent manner | Q44002224 | ||
| B-Cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients | Q44011620 | ||
| Is presensitization relevant to liver transplantation outcome? | Q44100307 | ||
| Monitoring of anti-HLA class I and II antibodies by flow cytometry in patients after first cadaveric kidney transplantation | Q73490438 | ||
| Evaluation of anti-human leukocyte antigen allo-immunization in pediatric cadaveric kidney transplantation | Q73579580 | ||
| An association between posttransplant antibody production and renal transplant rejection | Q73667914 | ||
| Predictive power of ELISA-detected anti-HLA class I antibodies in pediatric kidney transplantation | Q73669392 | ||
| Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients | Q73957828 | ||
| Association between a positive flow cytometry crossmatch and the development of chronic rejection in primary renal transplantation | Q74233902 | ||
| Donor-specific antibodies after transplantation by flow cytometry: relative change in fluorescence ratio most sensitive risk factor for graft survival | Q74250378 | ||
| Some recent work on tumor immunity | Q74317456 | ||
| Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells | Q74317809 | ||
| High panel reactive antibody against cross-reactive group antigens as a contraindication to renal allotransplantation | Q74362769 | ||
| Humoral alloreactivity in recipients of renal allografts as a risk factor for the development of delayed graft function | Q74376258 | ||
| Call for revolution: a new approach to describing allograft deterioration | Q74407750 | ||
| Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation | Q74416108 | ||
| Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts | Q74550738 | ||
| Postoperative flow cytometry crossmatch in living donor liver transplantation: clinical significance of humoral immunity in acute rejection | Q74592882 | ||
| The role of flow cytometry-detected IgG and IgM anti-donor antibodies in cardiac allograft recipients | Q74602300 | ||
| Capillary C4d deposition as a marker of humoral immunity in renal allograft rejection | Q74644344 | ||
| Management of the highly HLA- sensitized patient. A novel role for intravenous gammaglobulin | Q74815812 | ||
| Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg) | Q74815832 | ||
| Flow cytometry crossmatch: a sensitive technique for assessment of acute rejection in renal transplantation | Q77176031 | ||
| Vascular rejection post heart transplantation is associated with positive flow cytometric cross-matching | Q77354929 | ||
| Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation | Q77415463 | ||
| Ligation of HLA class I molecules on smooth muscle cells with anti-HLA antibodies induces tyrosine phosphorylation, fibroblast growth factor receptor expression and cell proliferation | Q77457124 | ||
| Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching | Q77781397 | ||
| Transfusion-related acute lung injury (TRALI) | Q77793434 | ||
| Sensitization of renal transplant candidates by cryopreserved cadaveric venous or arterial allografts | Q77801795 | ||
| Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report | Q77847551 | ||
| Mycophenolate mofetil suppresses the production of anti-blood type anitbodies after renal transplantation across the abo blood barrier: ELISA to detect humoral activity | Q44221098 | ||
| Almost all patients who are waiting for a regraft of a kidney transplant have anti-HLA antibodies | Q46126639 | ||
| Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action | Q46681755 | ||
| Humoral Antibodies in Renal Allotransplantation in Man | Q47784760 | ||
| Significance of the positive crossmatch test in kidney transplantation | Q47800073 | ||
| HLA class I and class II antibodies: monitoring before and after kidney transplantation and their clinical relevance | Q47913818 | ||
| Tortuosity of the white matter medullary arterioles is related to the severity of hypertension | Q48605379 | ||
| Serotyping for Homotransplantation. XXII, Specificity of Cytotoxic Antibodies Developing after Renal Transplantation | Q49177983 | ||
| HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. | Q50899711 | ||
| Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. | Q53659700 | ||
| Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. | Q53770407 | ||
| Susceptibility of liver allografts to high or low concentrations of preformed antibodies as measured by flow cytometry. | Q53966060 | ||
| Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. | Q54013696 | ||
| Acute rejection and the flow cytometry crossmatch. | Q54204663 | ||
| The role of IgA anti-HLA class I antibodies in kidney transplant survival. | Q54396198 | ||
| Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. | Q55034268 | ||
| Flow PRA to detect clinically relevant HLA antibodies | Q57793183 | ||
| Pretransplant and posttransplant monitoring of anti-HLA class I IgG1 antibodies by ELISA identifies patients at high risk of graft loss | Q58850734 | ||
| Glucocorticoid axis abnormalities related to brain damage | Q61774898 | ||
| Anti-endothelial antibodies and coronary artery disease after cardiac transplantation | Q67517643 | ||
| Pretransplant and posttransplant antibodies in human corneal transplantation | Q67564828 | ||
| Immunomodulation of kidney and heart transplants by anti-idiotypic antibodies | Q68060933 | ||
| Specificity of lymphocytotoxic antibodies formed after cardiac transplantation and correlation with rejection episodes | Q68153817 | ||
| Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome | Q68166622 | ||
| Antiidiotypic antibodies to human major histocompatibility complex class I and II antibodies in hepatic transplantation and their role in allograft survival | Q68166626 | ||
| Hyperacute and acute kidney graft rejection due to antibodies against B cells | Q68209607 | ||
| Posttransplant antidonor antibodies and graft rejection. Evaluation by two-color flow cytometry | Q69486597 | ||
| Soluble HLA antigens, anti-HLA antibodies, and antiidiotypic antibodies in the circulation of renal transplant recipients | Q70122017 | ||
| Association of anti-F(ab')2 antibodies with higher kidney transplant survival rates | Q70250271 | ||
| In vitro studies to explain high renal allograft survival in IgA nephropathy patients | Q70727451 | ||
| Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease | Q71023395 | ||
| Pulmonary Infiltrates Associated with Leukoagglutinin Transfusion Reactions | Q71143434 | ||
| Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema | Q71157326 | ||
| Hyperacute rejection following lung transplantation | Q71234138 | ||
| Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting heart transplantation. Fluorescence-activated cell sorter analysis | Q71588977 | ||
| Characterization of antiidiotypic antibodies to donor HLA that develop after liver transplantation | Q72092206 | ||
| The association of lymphocytotoxic antibodies with corneal allograft rejection in high risk patients. The Collaborative Corneal Transplantation Studies Research Group | Q72486878 | ||
| Capillary deposition of C4d complement fragment and early renal graft loss | Q72791721 | ||
| Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies | Q73100253 | ||
| Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection | Q73111913 | ||
| Anti-cell surface endothelial antibodies in sera from cardiac and kidney transplant recipients: association with chronic rejection | Q73231144 | ||
| Susceptibility of lung transplants to preformed donor-specific HLA antibodies as detected by flow cytometry | Q73253914 | ||
| Posttransplant donor-specific antibody characterization and kidney graft survival | Q73286062 | ||
| Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts | Q73338525 | ||
| Postoperative production of anti-donor antibody and chronic rejection in renal transplantation | Q73445495 | ||
| Successful cadaveric renal transplantation of patients highly sensitized to HLA Class I antigens | Q73490435 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 665-673 | |
| P577 | publication date | 2003-06-01 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Humoral theory of transplantation | |
| P478 | volume | 3 |
| Q35568505 | A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. |
| Q49925863 | A Comparison of HLA Molecular Mismatch Methods to Determine HLA Immunogenicity |
| Q42878989 | A clinical scoring system highly predictive of long-term kidney graft survival |
| Q51969757 | A non-allogeneic stimulus triggers the production of de novo HLA antibodies in healthy adults. |
| Q39470034 | A stepwise breakdown of B-cell tolerance occurs within renal allografts during chronic rejection |
| Q48032381 | ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates |
| Q50476173 | Acute antibody-mediated rejection possibly due to anti-human leukocyte antigen DQB1 antibodies after renal transplantation - case report. |
| Q46738364 | Acute humoral rejection of renal allografts in CCR5(-/-) recipients |
| Q37686066 | Advances in immunosuppression for renal transplantation. |
| Q35648369 | Allograft arteriopathy: pathogenesis update |
| Q36820105 | Allorecognition and the alloresponse: clinical implications |
| Q51033796 | Anti-HLA antibodies in heart transplantation. |
| Q46719461 | Anti-HLA antibodies in kidney transplanted patients |
| Q42639838 | Anti-HLA antibody profile of Turkish patients with end-stage renal disease. |
| Q37218092 | Anti-major histocompatibility complex class I-related chain A antibodies in organ transplantation |
| Q35611613 | Antibody to human leukocyte antigen triggers endothelial exocytosis |
| Q51278545 | Antibody-Mediated Rejection in Kidney Transplantation Without Evidence of Anti-HLA Antibodies? |
| Q47773036 | Antibody-mediated rejection in young kidney transplant recipients: the dilemma of noncompliance and insufficient immunosuppression |
| Q36131185 | Antibody-mediated rejection of single class I MHC-disparate cardiac allografts |
| Q38130585 | Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies |
| Q37332696 | Antibody-mediated rejection: treatment alternatives and outcomes. |
| Q84409945 | Antibody-mediated response in rat liver chronic rejection |
| Q47810103 | Association Between HLA Antibodies and Different Sensitization Events in Renal Transplant Candidates. |
| Q51545660 | Association of C1q Binding Status With De Novo HLA Antibody Clinical Features and Allograft Function in Kidney Transplantation Patients During Eight Years of Dynamic Follow-up. |
| Q47860610 | Association of HLA phenotypes of end-stage renal disease patients preparing for first transplantation with anti-HLA antibody status. |
| Q37528715 | Autologous and Allogenous Antibodies in Lung and Islet Cell Transplantation. |
| Q37782255 | B cells and transplantation tolerance |
| Q50870575 | B cells display an abnormal distribution and an impaired suppressive function in patients with chronic antibody-mediated rejection. |
| Q36429791 | B cells: a rational target in alloantibody-mediated solid organ transplantation rejection |
| Q34189435 | Bortezomib in kidney transplantation |
| Q33584895 | Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial |
| Q82944275 | C4d binding correlated with strong HLA antibodies involved in graft failures |
| Q46310957 | C4d deposition is associated with chronic allograft nephropathy in rats and could be influenced by immunosuppressants |
| Q46310951 | C4d deposition is correlated with the level of antivimentin antibody in rat kidneys undergoing chronic allograft nephropathy |
| Q40861983 | Cellular immune profile of kidney transplant patients developing anti-HLA antibodies during childhood |
| Q53229165 | Characterisation of Tertiary Lymphoid Organs in Explanted Rejected Donor Kidneys. |
| Q37058050 | Chronic alloantibody mediated rejection |
| Q46667111 | Chronic allograft nephropathy--clinical guidance for early detection and early intervention strategies |
| Q37394650 | Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses |
| Q84238174 | Chronic rejection of human kidney allografts |
| Q38265563 | Clinical relevance of HLA antibody monitoring after kidney transplantation |
| Q38079301 | Clinical relevance of antibody development in renal transplantation |
| Q46719552 | Clinical relevance of low levels of preformed alloantibodies detected by flow cytometry in the first year post-kidney transplantation |
| Q83061041 | Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA |
| Q35954850 | Compatibility and kidney transplantation: the way to go. |
| Q52860032 | Complement-fixing antibodies against denatured HLA and MICA antigens are associated with antibody mediated rejection. |
| Q51591791 | Conformational Variants of the Individual HLA-I Antigens on Luminex Single Antigen Beads Used in Monitoring HLA Antibodies: Problems and Solutions. |
| Q37836967 | Current approaches to the management of highly sensitized kidney transplant patients |
| Q38096463 | Current pharmacotherapeutical options for the prevention of kidney transplant rejection |
| Q84136247 | Cytotoxic crossmatch analysis before allo-SCT is a poor diagnostic tool for prediction of rejection |
| Q46938131 | DQ molecules are the principal stimulators of de novo donor-specific antibodies in nonsensitized pediatric recipients receiving a first kidney transplant. |
| Q38861456 | De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients. |
| Q30403833 | De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients |
| Q40468571 | De novo donor-specific anti-HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q-binding ability. |
| Q46792984 | De novo membranous nephropathy associated with donor-specific alloantibody |
| Q37685073 | Detecting adaptive immunity: applications in transplantation monitoring |
| Q53570974 | Detection and analysis of HLA class I and class II specific alloantibodies in the sera of dialysis recipients waiting for a renal retransplantation. |
| Q84871050 | Detection of plasma cells, C4d deposits and donor-specific antibodies on sequential graft biopsies of renal transplant recipients with chronic dysfunction |
| Q33867260 | Development of antibodies to human leukocyte antigen precedes development of antibodies to major histocompatibility class I-related chain A and are significantly associated with development of chronic rejection after human lung transplantation |
| Q46135152 | Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens |
| Q46045914 | Diagnosis and treatment of acute humoral kidney allograft rejection. |
| Q37308415 | Differential effects of donor-specific alloantibody |
| Q79854817 | Distribution of donor-specific antibodies in the cortex and the medulla of renal transplants with chronic allograft nephropathy |
| Q92803508 | Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure |
| Q36338297 | Donor-recipient sex mismatch in kidney transplantation |
| Q88972270 | Donor-specific Antibody Surveillance and Graft Outcomes in Pediatric Kidney Transplant Recipients |
| Q36126873 | Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy |
| Q47361366 | Donor-specific sensitization by cadaveric venous allografts used for arterial reconstruction in peripheral arterial occlusive vascular disease |
| Q58850604 | Dynamics of anti-human leukocyte antigen antibodies after renal transplantation and their impact on graft outcome |
| Q46245989 | Early and late humoral rejection: a clinicopathologic entity in two times |
| Q39512442 | Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. |
| Q57489285 | Effect of Perioperative Blood Transfusions in Renal Transplant Patients |
| Q27027082 | Effector mechanisms of rejection |
| Q37960177 | Emerging drugs for the treatment of transplant rejection |
| Q51354461 | EpHLA software: a timesaving and accurate tool for improving identification of acceptable mismatches for clinical purposes. |
| Q50177060 | EpHLA: an innovative and user-friendly software automating the HLAMatchmaker algorithm for antibody analysis |
| Q50902399 | Evaluation of a new flow cytometry crossmatch procedure for simultaneous detection of cytotoxicity and antibody binding. |
| Q41384256 | Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus. |
| Q36110114 | Expansion of polyreactive B cells cross-reactive to HLA and self in the blood of a patient with kidney graft rejection |
| Q46320618 | Factors influencing second renal allograft survival: a single center experience in China |
| Q33207800 | Flow cytometric detection of complement-activating HLA antibodies |
| Q37485481 | Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys |
| Q37590820 | From Humoral Theory to Performant Risk Stratification in Kidney Transplantation. |
| Q38723925 | Functional Immune Anatomy of the Liver-As an Allograft |
| Q53313782 | Gene expression in highly sensitized dialysis patients waiting for a kidney transplant: A real-time PCR analysis. |
| Q30318084 | Generation of donor-specific anti-human leukocyte antigen antibodies after the transplantation of a fully matched kidney allograft and its impact on the selection of a subsequent renal regraft: a case report |
| Q34147590 | H-Y antibody development associates with acute rejection in female patients with male kidney transplants |
| Q33786811 | HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs |
| Q39381834 | HLA Epitopes: The Targets of Monoclonal and Alloantibodies Defined |
| Q37658743 | HLA Genotyping in Patients with End-Stage Renal Disease Waiting For Cadaveric Renal Transplantation in Federation of Bosnia and Herzegovina |
| Q36584523 | HLA and MICA: targets of antibody-mediated rejection in heart transplantation. |
| Q36751659 | HLA antibody analysis: sensitivity, specificity, and clinical significance in solid organ transplantation |
| Q38165753 | HLA antibody screening in kidney transplantation: current guidelines |
| Q36858319 | HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP. |
| Q41699696 | High-grade proteinuria as a cardiovascular risk factor in renal transplant recipients |
| Q45963224 | Human leukocyte antigen and major histocompatibility complex class I-related chain A antibodies after kidney transplantation in Turkish renal transplant recipients. |
| Q36202286 | Human leukocyte antigen antibodies for monitoring transplant patients |
| Q46429041 | Humoral Reactivity of Renal Transplant-Waitlisted Patients to Cells From GGTA1/CMAH/B4GalNT2, and SLA Class I Knockout Pigs. |
| Q51990430 | Humoral sensitization against rejected grafts: specific antibodies to graft immunogenic amino acid triplets. |
| Q37535280 | Identification and characterization of kidney transplants with good glomerular filtration rate at 1 year but subsequent progressive loss of renal function |
| Q80405156 | Immunological status in three patients, thirty years after living related renal transplantation: antibody production in long-term survivors |
| Q43150813 | Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection |
| Q50247701 | Impact of Early Blood Transfusion After Kidney Transplantation on the Incidence of Donor-Specific Anti-HLA Antibodies |
| Q46873941 | Impact of HLA antibodies on transplant glomerulopathy. |
| Q46897107 | Impact of de novo donor-specific HLA antibodies detected by Luminex solid-phase assay after transplantation in a group of 88 consecutive living-donor renal transplantations |
| Q50747783 | Impact of post-transplant flow cytometric panel-reactive antibodies on late-onset hepatic venous outflow obstruction following pediatric living donor liver transplantation. |
| Q91936186 | Impact, Screening, and Therapy of HLA Antibodies in Patients before and after Lung Transplantation |
| Q35757098 | Importance of biopsy evaluation and the role of the pathologist in solid organ transplant programs |
| Q37375622 | Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation |
| Q33756027 | Increased erythrocyte C4D is associated with known alloantibody and autoantibody markers of antibody-mediated rejection in human lung transplant recipients |
| Q90163135 | Influence of Preformed Antibodies in Liver Transplantation |
| Q46963752 | Influence of preformed donor-specific antibodies and C4d on early liver allograft function |
| Q50607448 | Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro. |
| Q28201812 | Interview with Dr Paul Terasaki |
| Q27023312 | Issues in solid-organ transplantation in children: translational research from bench to bedside. |
| Q92418172 | It's About Everything: Validation and Optimization of 96-Well Tray Flow Cytometry Crossmatch |
| Q51585363 | Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss. |
| Q54213334 | Kidney transplant recipients treated with belatacept exhibit increased naïve and transitional B cells. |
| Q46056178 | Kidney transplantation in a recipient with anti-HLA antibody IgM positive |
| Q37854488 | Kidney transplantation in highly sensitized patients: are there options to overcome a positive crossmatch? |
| Q87252731 | Kidney transplantation: evaluation and clinical outcome of 237 recipients at low, medium, high, or strong immunological risk of rejection |
| Q50910367 | Late Failing Heart Allografts: Pathology of Cardiac Allograft Vasculopathy and Association With Antibody-Mediated Rejection. |
| Q40477268 | Late and early C4d-positive acute rejection: different clinico-histopathological subentities in renal transplantation. |
| Q93121340 | Late impact of preformed anti-HLA antibodies on kidney graft outcome |
| Q33974428 | Long-Term Effects of Antibodies against Human Leukocyte Antigens Detected by Flow Cytometry in the First Year after Renal Transplantation |
| Q43848201 | Long-term follow-up of non-HLA and anti-HLA antibodies: incidence and importance in renal transplantation |
| Q39640425 | Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates |
| Q38007085 | Luminex and antibody detection in kidney transplantation |
| Q33409582 | Luminex(®) and its applications for solid organ transplantation, hematopoietic stem cell transplantation, and transfusion |
| Q27012583 | Maternal microchimerism in biliary atresia: are maternal cells effector cells, targets, or just bystanders? |
| Q38597010 | Mechanisms underlying human genetic diversity: consequence for anti-graft antibody responses. |
| Q38262909 | Methodological aspects of anti-human leukocyte antigen antibody analysis in solid organ transplantation |
| Q44260404 | Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. |
| Q39466553 | Molecular diagnosis of antibody-mediated rejection in human kidney transplants |
| Q35594016 | Mycophenolate mofetil in solid-organ transplantation |
| Q43061583 | Mycophenolate mofetil: long-term outcomes in solid organ transplantation |
| Q91705730 | Next-generation sequencing methods to detect donor-derived cell-free DNA after transplantation |
| Q37379253 | Noncognate function of B cells in transplantation |
| Q53861449 | Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. |
| Q37058039 | Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. |
| Q37218105 | Patient outcomes after kidney allograft loss |
| Q37071116 | Pediatric lung transplantation: perspectives for the pathologist |
| Q28082746 | Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine |
| Q45972310 | Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. |
| Q51454635 | Pre-existing donor-specific antibodies are detrimental to kidney allograft only when persistent after transplantation. |
| Q41615009 | Pre-transplant low level HLA antibody shows a composite poor outcome in long-term outcome of renal transplant recipients |
| Q51038562 | Predicting kidney graft failure by HLA antibodies: a prospective trial. |
| Q54361889 | Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors. |
| Q80309077 | Presensitization accelerates chronic allograft rejection in a heterotopic rat tracheal allograft model with immunosuppression |
| Q33998148 | Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss. |
| Q40636545 | Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients |
| Q37723175 | Prevalence and risk factors for early chronic allograft nephropathy in a live related renal transplant program |
| Q46429084 | Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation |
| Q83220154 | Prevalence of HLA antibodies and its impact on graft function in a group of kidney transplant recipients: a cross-sectional study |
| Q38010231 | Prevention of antibody-mediated kidney transplant rejection |
| Q33755462 | Prevention trumps treatment of antibody-mediated transplant rejection |
| Q36501663 | Regulatory dendritic cell therapy in organ transplantation |
| Q37611251 | Renal Transplant Patients Biopsied for Cause and Tested for C4d, DSA, and IgG Subclasses and C1q: Which Humoral Markers Improve Diagnosis and Outcomes? |
| Q51188383 | Renal allograft outcome in recipients of positive-crossmatch combined liver-kidney transplantation. |
| Q38021620 | Renal allografts in plasma cell myeloma hematopoietic cell graft recipients: on the verge of an explosion? |
| Q64982205 | Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy. |
| Q37300446 | Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes |
| Q92104125 | Revisiting the liver's role in transplant alloimmunity |
| Q37729059 | Role of T cells in graft rejection and transplantation tolerance. |
| Q48290798 | Role of de novo donor-specific anti-HLA antibodies in kidney graft failure: A case-control study. |
| Q46311126 | Sensitivity, specificity and clinical relevance of different cross-matching assays in deceased-donor renal transplantation. |
| Q40386334 | Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure |
| Q61053434 | Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches |
| Q47558235 | Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. |
| Q92479116 | Sex-Specific Differences in HLA Antibodies after Pneumococcal Vaccination in Kidney Transplant Recipients |
| Q82137931 | Significance of donor-specific antibodies in acute rejection |
| Q81813237 | Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection |
| Q43898088 | Specificity and sensitivity of screening for anti-HLA antibodies in kidney allograft dysfunction. |
| Q35990853 | Strategies for minimizing immunosuppression in kidney transplantation |
| Q59257891 | Successful Combined Partial Auxiliary Liver and Kidney Transplantation in Highly Sensitized Cross-Match Positive Recipients |
| Q80944663 | Successful engraftment following HLA-mismatched cord blood transplantation for patients with anti-HLA Abs |
| Q80353025 | Successful engraftment in crossmatch-positive HLA-mismatched peripheral blood stem cell transplantation after depletion of antidonor cytotoxic HLA antibodies with rituximab and donor platelet infusion |
| Q83071651 | Successful engraftment of a second transplant from unrelated cord blood identifying acceptable HLA Ag mismatches as treatment for primary graft failure possibly mediated by anti-HLA Abs after 'mega-dose' haploidentical PBSC transplantation |
| Q43938205 | Successful management of factor IX inhibitor-associated nephrotic syndrome in a hemophilia B patient |
| Q47897051 | Swine Leukocyte Antigen Class II Is a Xenoantigen. |
| Q88656410 | The Approach to Antibodies After Heart Transplantation |
| Q28087773 | The Complement System and Antibody-Mediated Transplant Rejection |
| Q30397251 | The Humoral Theory of Transplantation: Epitope Analysis and the Pathogenicity of HLA Antibodies |
| Q42317060 | The Immunogenicity of HLA Class II Mismatches: The Predicted Presentation of Nonself Allo-HLA-Derived Peptide by the HLA-DR Phenotype of the Recipient Is Associated with the Formation of DSA. |
| Q39121357 | The Role of Humoral Alloreactivity in Liver Transplantation: Lessons Learned and New Perspectives. |
| Q36719246 | The clinical impact of humoral immunity in pediatric renal transplantation. |
| Q34973409 | The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children. |
| Q33872046 | The effect of stem cell transplantation on immunosuppression in living donor renal transplantation: a clinical trial |
| Q46105901 | The expression of B-cell activating factor belonging to tumor necrosis factor superfamily (BAFF) significantly correlated with C4D in kidney allograft rejection |
| Q86635362 | The impact of non-HLA antibodies directed against endothelin-1 type A receptors (ETAR) on early renal transplant outcomes |
| Q37563986 | The pathogenesis and treatment of chronic allograft nephropathy |
| Q35583534 | The role of B cells and alloantibody in the host response to human organ allografts |
| Q82064319 | The strength of donor-specific antibody is a more reliable predictor of antibody-mediated rejection than flow cytometry crossmatch analysis in desensitized kidney recipients |
| Q37690953 | The yin and yang of B cells in graft rejection and tolerance |
| Q33398129 | Thrombotic microangiopathy after living-donor liver transplantation |
| Q54117446 | Tofacitinib halts progression of graft dysfunction in a rat model of mixed cellular and humoral rejection. |
| Q43580802 | Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause |
| Q46702773 | Ultra-late antibody-mediated rejection 30 years after a living-related renal allograft |
| Q37832763 | Understanding crossmatch testing in organ transplantation: A case-based guide for the general nephrologist |
| Q28069336 | Unraveling the Role of Allo-Antibodies and Transplant Injury |
| Q37852766 | Uterine transplantation: a promising surrogate to surrogacy? |
| Q50504222 | Utility of protocol kidney biopsies for de novo donor-specific antibodies. |
| Q40634986 | Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss |
| Q46894292 | Variability in donor-specific alloantibody production after transplantation. |
| Q27024077 | Vascular endothelium as a target of immune response in renal transplant rejection |
| Q81680338 | Vimentin antibodies: a non-HLA antibody as a potential risk factor in renal transplantation |
| Q83446841 | XM-ONE detection of endothelium cell antibodies identifies a subgroup of HLA-antibody negative patients undergoing acute rejection |
| Q79979170 | [Alloantibodies-mediated kidney transplant rejection: a pair of continuing approaches, and with nonetheless many open questions] |
| Q81784352 | [Post-transplantation anti-HLA antibodies: which relevance?] |
| Q79979192 | [The discovery of capillary Cd4 in kidney transplantation and the "renaissance" of humoral rejection] |
Search more.